Published in
Oxford University Press, The Oncologist, 7(18), p. 795-801, 2013
DOI: 10.1634/theoncologist.2013-0065
Links
- ORCID
- ORCID
- Oxford University Press | PDF
- [www.ncbi.nlm.nih.gov] | PDF
- [europepmc.org] | PDF
- [www.researchgate.net] | PDF
- [www.ncbi.nlm.nih.gov] | PDF
Tools
Trastuzumab-Related Cardiotoxicity in Early Breast Cancer: A Cohort Study
Journal article published in 2013 by
Martina Bonifazi,
Matteo Franchi,
Marta Rossi,
Lorenzo Moja 
,
Alberto Zambelli ,
Antonella Zambon,
Giovanni Corrao,
Carlo La Vecchia,
Carlo Zocchetti,
Eva Negri
,
Alberto Zambelli ,
Antonella Zambon,
Giovanni Corrao,
Carlo La Vecchia,
Carlo Zocchetti,
Eva Negri
This paper is made freely available by the publisher.
Full text: Download
Data provided by 
Abstract
The cardiac safety profile of trastuzumab for adjuvant treatment of early stage breast cancer is unclear. This study assessed trastuzumab-related cardiotoxicity and its predictors in a large cohort of Italian women. The cardiotoxicity of trastuzumab was found to vary considerably across subgroups of patients, and the long-term safety profile was less favorable than that in the largest clinical trial.